HOME >> MEDICINE >> NEWS
Fred Hutchinson oversees two grants of nearly $8 million to develop blood test for breast cancer

The Fred Hutchinson Cancer Research Center will oversee two major grants totaling nearly $8 million to develop a blood test that can be used in conjunction with mammography to improve early detection of breast cancer.

The first, a $7 million, four-year Breast Cancer Center of Excellence grant to Fred Hutchinson from the U.S. Department of Defense, will involve investigators from 10 institutions in Seattle, Houston and Los Angeles. (Please see list.)

The second is a grant of nearly $1 million from a unique, multi-year, public-private partnership of the Avon Foundation and the National Cancer Institute called "Progress for Patients." The funds will be split equally among Fred Hutchinson, the University of Alabama, Fox Chase Cancer Center and M.D. Anderson Cancer Center. (Please see sidebar for more details about the Avon/NCI grant.)

Nicole Urban, Sc.D., a member of Fred Hutchinson's Public Health Sciences Division, will serve as principal investigator of both initiatives.

"Our goal for both projects is to evaluate a variety of breast-cancer biomarkers for their contribution to the early detection of breast cancer. Our vision is that a simple blood test could be used along with mammography to detect breast cancer early in the disease process. We are particularly interested in markers that identify aggressive forms of breast cancer that are missed by mammography," said Urban, also a research professor of health services in the UW School of Public Health and Community Medicine.

While mammography indeed saves lives - reducing deaths from breast cancer by up to 30 percent among women over age 50 - it misses about one in five breast cancers overall. Mammography is least effective in detecting cancer in younger women, who tend to have dense breast tissue that is difficult to X-ray. Other limitations of mammography in younger women include a high rate of false positives that result in unnecessary biopsies and the inability to distinguish between aggre
'"/>

Contact: Kristen Woodward
kwoodwar@fhcrc.org
206-667-5095
Fred Hutchinson Cancer Research Center
3-Oct-2002


Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Fred Hutchinson receives $9.7 million to lead early detection consortium
2. Fred Hutchinson uses IBM technology to help find genetic links to immune-system diseases
3. Fred Hutchinson Cancer Research Center study shows retinoids kill childhood brain tumor cells
4. Fred Hutchinson Research Center awarded $7 million grant
5. Fred Hutchinson receives $12.7 million to lead prostate-cancer consortium
6. Hutchinson Center receives $1.2 million from National Science Foundation to study plant genetics
7. Of vasectomies, vitamins and prostate-cancer risk: Hutchinson Center study examines the links
8. Fred Hutchinson Cancer Research Center And Targeted Genetics Corp. Publish Data On Adoptive Immunotherapy For HIV
9. UNH launches 2nd spinout company with NIH grants
10. Disease testing for immigrants: Discrimination disguised as public health policy
11. US FDA grants full approval to DOXIL(R) following submission of phase III data

Post Your Comments:
(Date:3/6/2015)... Lewisville, Texas (PRWEB) March 06, 2015 ... at 7am today. The new facility is located at 13351 ... , “Our experienced clinical team is ready 24-7 to provide ... said Dr. Grossman, Facility Medical Director of First Choice Emergency ... a ribbon cutting with the South Metro Denver Chamber of ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Utilizing the ... and rapidly reach their ideal weight has enabled Diet ... to their already impressive collection of fat loss ... existing clients special promotions and savings to help people ... immediately. This promotion is especially appealing to new ...
(Date:3/6/2015)... Aliso Viejo, California (PRWEB) March 06, 2015 ... entitled Pro3rd Hue from Pixel Film Studios. , “Pro3rd Hue ... style.” Said Christina Austin, CEO of Pixel Film Studios. “Blurring ... definite game changer.” , Pro3rd Hue is a set of ... Final Cut Pro X. With Pro3rd Hue, FCPX users can ...
(Date:3/6/2015)... Medical Products, Inc., a Mississippi Corporation, announced ... Healthcare to become an authorized distributor for GE Healthcare ... has 31 years in distribution within the U.S. and ... agreement, MPI will have the opportunity to extend services ... , MPI has always strived to provide our customers ...
(Date:3/5/2015)... global digital PCR (dPCR) and qPCR market is expected to reach ... 2019. , The global digital PCR (dPCR) and qPCR market is ... 2019. Although the mature markets such as the U.S., Germany, France ... qPCR market the Asia-Pacific region is expected to grow at the ... the digital PCR (dPCR) and qPCR market is driven by factors ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4
(Date:3/5/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... its financial results for the fourth quarter and full ... , Net Revenues Increased 21.3% Year Over Year to ... 17.7% Year Over Year to $140.5 Million , ...
(Date:3/5/2015)... and TÜBINGEN, Germany , March ... Gates Foundation and CureVac today announced that the ... million (€46 million) in CureVac, a leading clinical-stage ... part of the agreement, the foundation will also ... prophylactic vaccines based on CureVac,s proprietary messenger RNA ...
(Date:3/5/2015)... LITTLE FALLS, N.J. , March 5, 2015 ... the results for its second quarter ended January 31, 2015 ... a conference call to discuss the results at 11:00 AM ... dial (877) 407-8033 approximately 5 to 10 minutes before the ... a digital replay of the call will be available from ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
Cached News: